RxDoctor Payments Data

Jennifer Fox

Gerontology · Flemington, NJNPI 1225450950

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $49,544 of the $75,597 with a category attached, or 65.5%. 24 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 45.2% of the total. 2025 is the largest year on record at $38,028, more than ten times the $1,423 reported in 2021. Among gerontology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$75,597in general payments, 2019–2025

Across 314 payments — averaging $240.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$34K
  • Actelion Pharmaceuticals US, Inc.$26K
  • E.r. Squibb & Sons, L.L.C.$8K
  • Merck$2K
  • United Therapeutics Corporation$1K
  • Boehringer Ingelheim$1K
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$2,0403%
  • Speaking & faculty fees$49,54466%
  • Travel & lodging$12,84617%
  • Food & beverage$10,76614%
  • Education$4021%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,597 in reported general payments places this provider in the 95th percentile of 374 gerontology providers in New Jersey.

See all gerontology providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis31$681,258
WinrevairSotatercept-Csrk11$273,421
OpsumitMacitentan15$189,074
CamzyosMavacamten23$187,124
AdempasRiociguat13$157,329
EntrestoSacubitril/Valsartan57$84,888
AdcircaTadalafil15$76,626
JardianceEmpagliflozin53$71,954
EliquisApixaban49$52,354
FarxigaDapagliflozin Propanediol29$36,926
XareltoRivaroxaban20$25,086
Everolimus12$10,685
Sildenafil Citrate23$5,733
Torsemide54$2,339
Metoprolol Succinate94$1,332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$168$733,61180 claims
MerckWinrevair$1,573$273,42111 claims
Actelion Pharmaceuticals US, Inc.Opsumit$26,420$189,07415 claims
E.r. Squibb & Sons, L.L.C.Camzyos$7,747$187,12423 claims
BayerAdempas$318$157,32913 claims
NovartisEntresto$52$84,88857 claims
United Therapeutics CorporationAdcirca$1,140$76,62615 claims
Boehringer IngelheimJardiance$1,050$71,95453 claims
AstraZenecaFarxiga$473$36,92629 claims
Johnson & JohnsonXarelto$112$25,08620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 374 gerontology providers in New Jersey.

Other gerontology in Flemington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →